Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in U.S. adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008 Jul;156(1):112-9.
 Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007 Oct-Nov;58(5):513-22.
 Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C7-12.
 Halvorsen B, Otterdal K, Dahl TB, Atherosclerotic plaque stability--what determines the fate of a plaque? Prog Cardiovasc Dis. 2008 Nov-Dec;51(3):183-94
 Blackburn P, Côté M, Lamarche B, et al. Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size. Metabolism. 2003 Nov;52(11):1379-86.
 Stanhope KL, Bremer AA, Medici V, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab. 2011 Oct;96(10):E1596-605.
 Kokkinos P. Physical activity and cardiovascular disease prevention: current recommendations. Angiology. 2008 Apr-May;59(2 Suppl):26S-9S.
 Moholdt T, Wisløff U, Nilsen TI, Physical activity and mortality in men and women with coronary heart disease: a prospective population-based cohort study in Norway (the HUNT study). Eur J Cardiovasc Prev Rehabil. 2008 Dec;15(6):639-45.
 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004 May 19;43(10):1731-7.
 Navas-Acien A, Guallar E, Silbergeld EK, et al. Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect. 2007 Mar;115(3):472-82.
 Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005 Feb;6(1):27-36.
 Prozialeck WC, Edwards JR, Nebert DW, et al. The vascular system as a target of metal toxicity. Toxicol Sci. 2008 Apr;102(2):207-18.
 Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006 Jan 26;106(3):291-7.
 Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
 Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A-41A.
 Ip S, Lichtenstein AH, Chung M, Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med. 2009 Apr 7;150(7):474-84.
 Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep;32(9):482-6.
 Shin MJ, Krauss RM. Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men. Atherosclerosis. 2010 Feb 24. [Epub ahead of print]
 Rasouli M, Kiasari AM. Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease. Clin Chem Lab Med. 2008;46(5):667-73
 Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008 Dec 1;102(11):1540-4.
 Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007 Jun 11;167(11):1159-65.
 Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340-9.
 Wang TJ, Pencina MJ, Booth SL Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008 Jan 29;117(4):503-11.
 Jung UJ, Torrejon C, Tighe AP, et al. n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am J Clin Nutr. 2008 Jun;87(6):2003S-9S.
 Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract. 2003 May;57(4):305-14.
 He K, Liu K, Daviglus ML, Mayer-Davis E, et al. Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr. 2008 Oct;88(4):1111-8.
 Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40.
 Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising highdensity lipoprotein cholesterol levels. Heart. 2008 Jun;94(6):706-14.
 Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006 Sep 5;98(6):743-5.